Targeting Renal Cell Carcinoma with Gambogic Acid in Combination with Sunitinib in Vitro and in Vivo |
Jiang, Xiao-Liang
(Department of Urology, The First Affiliated Hospital, Chongqing Medical University)
Zhang, Yao (Department of Urology, The First Affiliated Hospital, Chongqing Medical University) Luo, Chun-Li (Department of Laboratory Medicine, Chongqing Medical University) Wu, Xiao-Hou (Department of Urology, The First Affiliated Hospital, Chongqing Medical University) |
1 | Lu L, Tang D, Wang L, et al (2012). Gambogic acid inhibits TNF-alpha-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-kappaB signaling pathways. Acta Pharmacol Sin, 33, 531-41. DOI ScienceOn |
2 | Lu N, Yang Y, You Q D, et al (2007). Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/ Flk-1. Cancer Lett, 258, 80-9. DOI ScienceOn |
3 | Medema RH, Klompmaker R, Smits VA, Rijksen G (1998). p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stressactivated kinases. Oncogene, 16, 431 -41. DOI ScienceOn |
4 | Merseburger AS, Kuczyk MA (2008). Value of targeted therapies for renal cell cancer. Urologe, 47, 1303-10. DOI |
5 | Miyake M, Anai S, Fujimoto K, et al (2012). 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncol Lett, 3, 1195-202. |
6 | Motzer RJ, Hudes GR, Ginsberg MS, et al (2010). Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Am J Clin Oncol, 33, 614-8. DOI ScienceOn |
7 | Motzer RJ, Michaelson MD, Redman BG, et al (2006a). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24. DOI ScienceOn |
8 | Motzer RJ, Rini BI, Bukowski RM, et al (2006b). Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295, 2516-24. DOI ScienceOn |
9 | Pandey MK, Sung B, Ahn KS, et al (2007). Gambogic acid, a novel ligand for transferrin receptor, potentiates TNFinduced apoptosis through modulation of the nuclear factorkappaB signaling pathway. Blood, 110, 3517-25. DOI ScienceOn |
10 | Qi Q, Gu H, Yang Y, et al (2008). Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med (Berl), 86, 1367-77. DOI ScienceOn |
11 | Rini BI, Atkins MB (2009). Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol, 10, 992-1000. DOI ScienceOn |
12 | Rong JJ, Hu R, Qi Q, et al (2009). Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53. Cancer Lett, 284, 102-12. DOI ScienceOn |
13 | Saito Y, Tanaka Y, Aita Y, et al (2012). Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD. Am J Physiol Endocrinol Metab, 302, E615-25. DOI |
14 | Uetsuka H, Haisa M, Kimura M, et al (2003). Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res, 289, 27-35. DOI ScienceOn |
15 | Wang J, Liu W, Zhao Q, et al (2009). Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology, 256, 135-40. DOI ScienceOn |
16 | Abdelnour-Berchtold E, Cerantola Y, Roulin D, et al (2010). Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin. Anticancer Res, 30, 799-804. |
17 | Ando T, Kawabe T, Ohara H, et al (2001). Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem, 276, 42971-7. DOI ScienceOn |
18 | Asano J, Chiba K, Tada M, et al (1996). Cytotoxic xanthones from Garcinia hanburyi. Phytoch mistry, 41, 815-20. DOI ScienceOn |
19 | Dudek AZ, Zolnierek J, Dham A, et al (2009). Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer, 115, 61-7. DOI ScienceOn |
20 | Feldman DR, Baum MS, Ginsberg MS, et al (2009). Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol, 27, 1432-9. DOI ScienceOn |
21 | Gary H, Michael C, Piotr T, et al (2007). Temsirolimus, Interferon Alfa,or Both for Advanced Renal-Cell Carcinoma. N Engl J Med, 356, 2271-81. DOI ScienceOn |
22 | Gu H, Rao S, Zhao J, et al (2009). Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol, 135, 1777-82. DOI ScienceOn |
23 | Iwata H, Sato H, Suzuki R, et al (2011). A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma. Int J Oncol, 38, 1653-61. |
24 | Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. DOI ScienceOn |
25 | Kausch I, Jiang H, Thode B, et al (2005). Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma. Eur Urol, 47, 703-9. DOI ScienceOn |
26 | Li C, Lu N, Qi Q, et al (2011). Gambogic acid inhibits tumor cell adhesion by suppressing integrin beta1 and membrane lipid rafts-associated integrin signaling pathway. Biochem Pharmacol, 82, 1873-83. DOI ScienceOn |
27 | Wang T, Wei J, Qian X, et al (2008). Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett, 262, 214-22. DOI ScienceOn |
28 | Yu J, Guo QL, You QD, et al (2007). Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis, 28, 632-8. |
29 | Zhang L, Yi Y, Chen J, et al (2010). Gambogic acid inhibits Hsp90 and deregulates TNF-alpha/NF-kappaB in HeLa cells. Biochem Biophys Res Commun, 403, 282-7. DOI |